ABUSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Arbutus Biopharma Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$4.23+0.01 (+0.24%)
Close on Oct 19, 2026
- Market cap
- $835.30M
- P/E (TTM)
- 5.4
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
-271.0%+565.1 pts over 5 years
Net margin
-237.9%+684.1 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +128.2% | -28.8% | +15.3% | -4.9% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -102.4% | -73.0% | -38.5% | |
| Return on assets | -77.7% | -52.5% | -29.6% | |
| Current ratio | 12.52 | 13.38 | 15.73 | |
| Interest coverage | – | -14.4× | -393.4× | |
| Capex to revenue | 268.0% | 3.3% | 0.0% | |
| Diluted shares | 53M | 76M | 192M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Arbutus Biopharma generated $293.31M from operations and spent $2.51M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$293.31M
Used
$2.51M
Capital expenditure$2.51M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-237.9%
×Asset turnover0.12×
×Equity multiplier1.30×
=Return on equity, FY2025-38.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -237.9% | 0.12× | 1.30× | -38.5% |
| FY2024 | -1133.0% | 0.04× | 1.36× | -68.8% |
| FY2023 | -401.6% | 0.11× | 1.40× | -60.0% |
| FY2022 | -178.0% | 0.20× | 1.31× | -45.4% |
| FY2021 | -693.9% | 0.06× | 1.26× | -56.2% |
| FY2020 | -922.0% | 0.06× | 1.39× | -73.0% |
| FY2019 | -2557.4% | 0.04× | 1.22× | -112.6% |
| FY2018 | -959.8% | 0.03× | 1.22× | -29.8% |
| FY2017 | -788.9% | 0.04× | 1.33× | -43.8% |
| FY2016 | -25765.5% | 0.00× | 1.32× | -102.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$33.50M
- Cash generatingOperating cash flow above zero-$39.64M
- Return on assets improvedROA up on the prior year-48.4% → -25.4%
- Earnings backed by cashOperating cash flow above net income-$39.64M vs -$33.50M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose8.15 → 15.73
- No dilutionShare count did not rise186M → 192M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.04 → 0.11